Equities

Guided Therapeutics Inc

GTHP:QBB

Guided Therapeutics Inc

Actions
  • Price (USD)0.09
  • Today's Change-0.008 / -8.24%
  • Shares traded224.96k
  • 1 Year change-45.39%
  • Beta0.4741
Data delayed at least 15 minutes, as of Jun 10 2024 20:31 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.

  • Revenue in USD (TTM)82.00k
  • Net income in USD-3.23m
  • Incorporated1992
  • Employees4.00
  • Location
    Guided Therapeutics IncSuite 300, 4955 Avalon Ridge PkwyNORCROSS 30071United StatesUSA
  • Phone+1 (770) 242-8723
  • Fax+1 (770) 242-8639
  • Websitehttps://www.guidedinc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nu-Med Plus Inc0.00-119.16k4.19m2.00---------0.0014-0.00140.00-0.0020.00----0.00-350.01-447.69---------------22.74--------3.56------
Arch Therapeutics Inc130.55k-8.43m4.22m8.00------32.34-3.68-3.680.0425-2.450.08330.0637--16,318.75-538.25-188.28---804.6333.37---6,458.14-26,945.920.0164-1.27----383.83---32.35---21.76--
Hawkeye Systems Inc0.00-804.18k4.24m44.00---------0.1186-0.11860.00-0.290.00-------66.07-330.11-----------218.49---2.7810.45------4.85------
Sharps Technology Inc0.00-8.71m4.63m3.00--0.675-----0.6204-0.62040.000.43780.00-------74.67---95.84----------0.492--0.00-------112.12------
Vapotherm Inc70.07m-54.94m4.66m182.00------0.0665-8.62-8.6211.00-11.020.81221.467.53385,011.00-63.68-49.73-587.27-62.5445.2843.56-78.40-78.990.1259-1.272.59--2.8010.1448.62---10.38--
ADM Tronics Unlimited Inc2.85m-716.86k4.74m7.00--4.30--1.67-0.0106-0.01060.04210.01630.97723.854.25---24.62-11.45-38.81-15.7738.4543.73-25.19-15.281.24--0.2902--14.66-0.415993.04------
Bioelectronics Corp1.61m-289.82k4.94m9.00------3.07-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
BIOLASE Inc48.83m-38.26m5.01m157.00------0.1025-20.50-20.508.640.00811.282.219.00311,006.40-55.75-49.28-118.58-85.8034.2535.27-43.56-50.720.6409-5.980.9812--1.451.27-30.39--18.63--
Predictive Oncology Inc1.96m-14.78m5.33m34.00--1.30--2.72-3.66-3.660.48530.99770.10991.714.9557,642.65-82.89-91.80-108.54-126.2964.1864.64-754.19-1,419.991.35--0.0093--18.244.7545.67--5.44--
Guided Therapeutics Inc82.00k-3.23m5.46m4.00------66.61-0.0623-0.06230.0016-0.07210.03740.090411.7120,500.00-137.80-136.13----32.9329.39-3,685.37-3,666.670.1138-11.13----653.8511.4524.40------
ReShape Lifesciences Inc8.34m-10.92m5.49m31.00--1.21--0.6591-2.30-2.300.73190.19330.67810.81784.52268,871.00-88.83-136.06-162.20-194.3265.8556.30-130.99-408.361.26--0.00---22.79-0.947475.36---49.29--
Nexalin Technology Inc158.86k-4.94m5.54m6.00--2.38--34.85-0.6676-0.66760.02150.31290.03630.177844.0126,476.67-112.76---139.94--82.54---3,110.58--4.75--0.00---91.62---173.80------
Encision Inc6.87m-448.00k5.88m31.00--2.68--0.857-0.0381-0.03810.58350.18631.641.967.84221,520.00-10.69-1.07-14.05-1.4650.5452.27-6.52-0.6131.08-6.220.1123---4.17-3.44-393.90--12.89--
Fuse Medical Inc18.40m3.63m6.06m31.002.28--1.640.32950.0360.0360.2307-0.00310.95930.70185.75593,671.9018.910.750448.451.3564.9554.9819.720.65520.3143-1.131.12---8.67-6.72295.1134.66----
Sonendo Inc40.19m-57.74m6.21m216.00--0.2530--0.1545-0.6125-0.55520.4260.34820.44482.077.58186,055.60-63.91---78.82--27.64---143.67--2.14-10.830.4695--5.30---6.78------
Sigyn Therapeutics Inc0.00-3.56m6.43m5.00---------3.04-3.040.00-3.280.00----0.00-724.37-493.15-----------10,223.960.0199-1.92---------41.51------
Data as of Jun 10 2024. Currency figures normalised to Guided Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

7.34%Per cent of shares held by top holders
HolderShares% Held
Auctus Fund Management LLCas of 13 Mar 20244.08m7.34%
Rosalind Advisors, Inc.as of 31 Dec 20230.000.00%
Data from 13 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.